2 citations
,
September 2011 in “Der Urologe” Prostate cancer prevention now focuses on healthy diets and some medications, not vitamins.
June 2025 in “CA A Cancer Journal for Clinicians” Transgender men need personalized cancer care and continued testosterone therapy for well-being.
September 2025 in “Consilium Medicum” 5α-reductase inhibitors help manage symptoms of benign prostatic hyperplasia and may also prevent prostate cancer and treat hair loss.
November 2022 in “Molecular Pharmaceutics” cp-asiAR may effectively treat androgenetic alopecia by promoting hair growth and reducing androgen receptor activity.
April 2023 in “Journal of Investigative Dermatology” cp-asiAR may effectively treat hair loss by targeting androgen receptors.
April 2024 in “The Journal of urology/The journal of urology” SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
3 citations
,
May 2017 in “Bioorganic & medicinal chemistry letters” New compounds were made that are promising for prostate cancer therapy.
1 citations
,
May 2024 in “Human Genomics” Polygenic risk scores can predict the risk and outcomes of benign prostatic hyperplasia.
September 2024 in “Uro-Technology Journal”
June 2023 in “Research Square (Research Square)” A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.
August 2019 in “The Journal of Urology” Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.
1 citations
,
December 2013 in “Urological Science” A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.
1 citations
,
January 2021 in “Research Square (Research Square)” Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
March 2011 in “European Urology Supplements” CEC levels may be a useful marker for predicting prostate cancer progression.
February 2004 in “Oncology Times” Green tea extract and cycling hormone treatments may help treat advanced prostate cancer.
August 2016 in “Journal of Investigative Dermatology”
April 2010 in “The Journal of Urology” The research found that androgens help control blood flow in the rat prostate through a specific binding site.
October 2014 in “Cancer research” Blocking mTORC1 reduces skin tumor growth in mice.
February 2016 in “Journal of urology and nephrology open access” Finasteride, a drug that prevents testosterone conversion, can effectively reduce blood loss in prostate surgery, especially for patients with a prostatic volume over 30 cc, and decrease post-surgery complications.
1 citations
,
November 2015 in “Cochrane library” 5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
Finasteride may help prevent prostate cancer, but more research is needed.
April 2012 in “The Journal of Urology” More prostate biopsies increase the chance of finding cancers that may not need treatment.
April 2012 in “Cancer research” Blocking mTORC1 may help prevent skin cancer by stopping the growth of certain skin stem cells.
3 citations
,
June 2018 in “Bioorganic & medicinal chemistry” Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.
15 citations
,
March 2015 in “PloS one” Scientists restored fertility in male mice lacking a key fertility gene by using a modified gene.
July 2024 in “Reactions Weekly” 1 citations
,
August 2019 in “Journal of pediatric & adolescent gynecology” A new genetic change causing early stop in the androgen receptor gene was found in a patient with androgen insensitivity syndrome.
710 citations
,
May 2023 in “European Urology” Prostate cancer is common, but risk can be reduced by avoiding smoking, unhealthy diet, inactivity, certain medications, and risky jobs.
5 citations
,
July 2022 in “Orphanet journal of rare diseases” RSPO1 mutations in certain patients lead to skin cells that don't develop properly and are more likely to become invasive, increasing the risk of skin cancer.